Navigation Links
The Medicines Company's Cangrelor - Is it better than Plavix for Acute Coronary Syndrome?
Date:11/26/2013

DUBLIN, Nov. 26, 2013 /PRNewswire/ --Research and Markets (http://www.researchandmarkets.com/research/h45rfk/the_medicines) has announced the addition of the "The Medicines Company's Cangrelor - Is it better than Plavix for Acute Coronary Syndrome?" report to their offering.

(Logo: http://photos.prnewswire.com/prnh/20130307/600769)

Cangrelor is a reversible, intravenous inhibitor of the P2Y12 receptor whose effect is to inhibit adenosine diphosphate-induced platelet aggregation. The Medicines Company is developing it for use in the setting of patients undergoing percutaneous coronary intervention procedures (PCI), specifically those who have not used Plavix or other P2Y12 inhibitors in the prior week. Two previous phase III trials failed to meet their primary endpoints. Thus, approval hangs on the results of a third trial, CHAMPION-PHOENIX that should report before year-end. This report explores the probability of a favorable phase III outcome, eventual approval, and the market opportunity.

Key Topics Covered:

INTRODUCTION

1. Acute coronary syndromes (ACS)

2. Thrombosis is at the center of causality

3. Clinicians use several approaches to platelet inhibition


CANGRELOR

1. Phase I/II trials

2. Pivotal trials


CLINICAL AND REGULATORY DISCUSSION

1. Why did CHAMPION-PCI and CHAMPION-PLATFORM fail?

2. Given the PCI and PLATFORM results, what are the lessons for PHOENIX?

3. Are there meaningful safety concerns associated with cangrelor?

4. Are there any bleeding concerns?

5. Possible adverse pulmonary effects of cangrelor

6. What are the regulatory issues that cangrelor will face?

7. Other relevant FDA guidance

8. In summary

MARKET OPPORTUNITY

1. Overview of issues

2. Market estimates

3. Pipeline products

Companies Mentioned

  • Eli Lilly,
  • Bristol Myers Squibb,
  • Astra Zeneca

For more information visit http://www.researchandmarkets.com/research/h45rfk/the_medicines

About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Laura Wood , +353-1-481-1716, press@researchandmarkets.net




'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Worlds Only USDA Certified Organic and FDA Registered Homeopathic Medicines Guaranteed to Work
2. Lilly Expands Strategic Partnership with Chinese Manufacturer Novast to Serve Chinese Patients with High-Quality Branded Generic Medicines
3. Warning: Not All Cold Sore Medicines Are Created Equal
4. Kick Off Summer Vacation With Five Simple Tips to Safely Store Medicines While Traveling
5. Global pharmaceutical industry calls for broad-based cooperation to fight online sales of counterfeit medicines around the world
6. Unigene Provides Update Following Recent EMA Recommendation on Calcitonin-Containing Medicines
7. New Research Reveals Extent of Poor-Quality Antimalarial Medicines in South American Countries
8. Watson Applauds GPhA Study Demonstrating $1 Trillion in Prescription Drug Savings from Generic Medicines
9. Sigma-taus Antimalarial Awarded "Project of the Year" 2011 by Medicines for Malaria Venture
10. National Community Pharmacists Association and Purdue Pharma Urge Americans to Safeguard Rx Medicines This Holiday Season
11. PTC Therapeutics Announces European Medicines Agency Validation of Marketing Authorization Application for Ataluren in Duchenne Muscular Dystrophy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... a startling report released today, National Safety Council research ... proven plan to eliminate prescription opioid overdoses. Prescription Nation ... tackling the worst drug crisis in recorded U.S. history, assigned a ... , New Mexico , Tennessee ... failing states, three – Michigan , ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... , June 23, 2016 , ... on Thursday, July 7, 2016 , , , , LOCATION: ... , , , , EXPERT PANELISTS:  , , , ... Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and ... The global pharmaceutical industry is witnessing an exceptional era. ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room ... Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of ... too high can result in disappointment, perhaps even self-loathing. However, those who set the ... Research from PsychTests.com reveals that behind the tendency to set low expectations ...
(Date:6/24/2016)... PASADENA, CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. ... he would lash out at his family verbally and physically. , “When something upset him, ... table, he would use it. He would throw rocks at my other children and say ...
(Date:6/24/2016)... ... 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited to ... Recovery® program to drive cancer patients to and from their cancer treatments. Comfort ... quality of life and ongoing independence. Getting to and from medical treatments is ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, affiliated ... Weintraub as a prominent plastic surgeon and the network’s newest partner. , ... most handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands ...
Breaking Medicine News(10 mins):